Literature DB >> 25872110

Smoking is a predictor of adverse pathological features at radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital database.

Daniel F Zapata1, Lauren E Howard1,2, William J Aronson3, Christopher J Kane4, Martha K Terris5, Christopher L Amling6, Matthew R Cooperberg7, Stephen J Freedland1,2.   

Abstract

OBJECTIVE: To test the relationship of smoking and aggressive prostate cancer in men undergoing radical prostatectomy.
METHODS: A retrospective analysis of 2290 men who underwent radical prostatectomy from the Shared Equal Access Regional Cancer Hospital database from 2000 to 2013 was carried out. There were 1592 (70%) non-smokers and 698 (30%) smokers at radical prostatectomy. Logistic regression was used to examine whether smoking predicted Gleason score (≥4 + 3), margin status, extracapsular extension or seminal vesicle invasion. Linear regression was used to test the relationship between smoking and tumor volume.
RESULTS: Smokers were younger, more likely to be black, had lower body mass index, higher pathological Gleason score, more positive margins and extracapsular extension (all P < 0.05) versus non-smokers. On crude analysis, smoking was associated with positive margins (odds ratio 1.32; P = 0.003) and extracapsular extension (odds ratio 1.26; P = 0.036). After adjusting for multiple clinical factors, smoking remained associated with a 19-35% increased risk of every adverse feature studied, though only the association with extracapsular extension reached significance. On multivariable analysis, a trend for smokers to have larger tumor volumes (geometric mean 5.8 vs 5.3 g; P = 0.062) was found.
CONCLUSIONS: In patients undergoing radical prostatectomy, there seems to be a trend for smokers to have worse pathological features compared with non-/former smokers. If confirmed in future studies, smoking should be considered a modifiable risk factor for aggressive prostate cancer.
© 2015 The Japanese Urological Association.

Entities:  

Keywords:  pathology; prostatectomy; prostatic neoplasms; risk; smoking

Mesh:

Substances:

Year:  2015        PMID: 25872110     DOI: 10.1111/iju.12773

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  4 in total

1.  Association of Smoking Status With Recurrence, Metastasis, and Mortality Among Patients With Localized Prostate Cancer Undergoing Prostatectomy or Radiotherapy: A Systematic Review and Meta-analysis.

Authors:  Beat Foerster; Carmen Pozo; Mohammad Abufaraj; Andrea Mari; Shoji Kimura; David D'Andrea; Hubert John; Shahrokh F Shariat
Journal:  JAMA Oncol       Date:  2018-07-01       Impact factor: 31.777

2.  Circulating microRNAs in plasma among men with low-grade and high-grade prostate cancer at prostate biopsy.

Authors:  Alicia C McDonald; Manish Vira; Vonn Walter; Jing Shen; Jay D Raman; Martin G Sanda; Dattatraya Patil; Emanuela Taioli
Journal:  Prostate       Date:  2019-04-08       Impact factor: 4.104

3.  [What do prostate cancer patients know about smoking? : Results of a bicentric questionnaire study (KRAUT study)].

Authors:  M May; C Gilfrich; P Spachmann; O Maurer; M K Dombrowski; H M Fritsche; M Wöhr; S Brookman-May; T Karl; M Schostak; M Burger; S Lebentrau
Journal:  Urologe A       Date:  2016-08       Impact factor: 0.639

4.  Functional role and tobacco smoking effects on methylation of CYP1A1 gene in prostate cancer.

Authors:  Yozo Mitsui; Inik Chang; Taku Kato; Yutaka Hashimoto; Soichiro Yamamura; Shinichiro Fukuhara; Darryn K Wong; Marisa Shiina; Mitsuho Imai-Sumida; Shahana Majid; Sharanjot Saini; Hiroaki Shiina; Koichi Nakajima; Guoren Deng; Rajvir Dahiya; Yuichiro Tanaka
Journal:  Oncotarget       Date:  2016-08-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.